Two-Step Donor Stem Cell Transplant for Blood Cancers: Enhancing Cancer-Fighting Effects Safely

Program Overview

This phase II study is testing how well a donor stem cell transplant works for patients with high-risk blood cancers. Before the transplant, patients receive total-body irradiation and chemotherapy to stop the growth of both normal and cancerous cells in the bone marrow. This process also helps prevent the patient's immune system from rejecting the donor's stem cells. Once the healthy donor stem cells are infused, they can help the patient's bone marrow produce new blood cells and replace the patient's immune cells, potentially destroying any remaining cancer cells.

Description

The main goal of this study is to see if patients with high-risk blood cancers can have a better chance of survival two years after receiving a two-step donor stem cell transplant. Researchers are also looking at how often the cancer comes back within two years, the side effects of the treatment, and how well the new immune cells grow and recover.

Patients eligible for this study are those with high-risk blood cancers where a donor stem cell transplant is considered the best option for a cure. This includes patients whose cancer is stable or only slightly progressing after treatment, or those with untreated cancers where a transplant is the best chance for a cure. Patients must have a related donor whose immune markers are not a perfect match, and they must have good organ function and overall health.

The study will not include patients with certain health conditions, such as active brain cancer involvement, psychiatric disorders that prevent consent, or those who cannot tolerate the necessary treatments. Pregnant individuals or those unwilling to use contraception are also excluded.

Eligibility Criteria